Bristol Myers Squibb Third Quarter 2026 Earnings - BRISTOL MYERS SQUIBB CO

Financial Performance:

• Total revenue increased 7% year-over-year to approximately $13.1 billion in Q3 2026.
• Growth portfolio revenue rose 12% to $7.7 billion, while legacy portfolio revenue increased 1%, driven by Eliquis growth offsetting generic declines.
• Key product performance: Eliquis (+26% to $4.7B), Cuvantic (+28% sequentially, annualizing >$1.3B), Breonzi (+48% to $526M), Chemzios (+42% to $420M), Updevo (-6% to $2.4B), Opzelura (double-digit growth), and CoBentfi (+33% to $57M).
• Gross margin was 68.4%, and diluted earnings per share (EPS) were $1.35 per share (including $0.58 from acquired and in-process R&D).
• Strong cash flow generation with $4.2 billion in operating cash flow for the quarter; cash equivalents and marketable securities stood at approximately $13 billion.
• Operating expenses were $4.1 billion, supported by strategic productivity initiatives.

Guidance and Future Outlook:

• Full-year non-GAAP EPS guidance raised to a range of $6.35–$6.55, reflecting an increase of approximately $0.15 per share excluding one-time R&D charges.
• Legacy portfolio revenue decrease is now expected to be 3–5% for 2026, while Eliquis growth is projected to remain 20–25% for the full year.
• Management expects to sustain momentum with eight growth portfolio medicines annualizing over $1 billion each.
• Key upcoming readouts include Phase 3 data for melvexian in secondary stroke prevention (Q4 2026) and atrial fibrillation (Q1 2027), plus SOTIC2 in lupus (year-end 2026).
• Long-term goals include delivering sustained growth into the next decade through pipeline innovation and a disciplined capital allocation strategy.

Business Segments and Product Lines:

• Oncology: Accelerated approval of Zembexis (first FDA-approved cell mod for multiple myeloma); Mezignamide PDUFA date set for May 13, 2027; positive Phase 2 data for Arlocell in post-BCMA multiple myeloma; RAISE-101 (alpha-emitting RPT) showed promising interim PFS data in GEPNETs.
• Cardiovascular/Immunology: Chemzios expanded for pediatric obstructive HCM; SOTIC2 advancing in psoriatic arthritis and lupus.
• Neuroscience: Positive early launch feedback for CoBentfi in schizophrenia; new data presented on Alzheimer's disease psychosis (ADEPT studies).
• Pipeline Advancements: Admilpirant met primary endpoint in IPF (60mg dose); plans for a new $2.3B manufacturing campus in Houston and a $170M radiopharmaceutical facility in Indiana.
• Commercial Focus: Transition from IV to subcutaneous administration for Cuvantic (17% conversion achieved); Zembexis and Mezignamide positioned as foundational therapies in community settings.

Market and Competitive Landscape:

• Zembexis addresses a significant need in multiple myeloma as the only approved cell mod, competing against Revlimid and pomalidomide-based regimens.
• IPF market estimated at $4B, expected to nearly double with the advent of new disease-modifying therapies and a growing switch/add-on market.
• Radiopharmaceuticals positioned as a key growth platform, with RAISE-101 offering a potential standard of care after lutetium-based therapy for GEPNETs.
• Management notes that market share gains are occurring for Eliquis despite upcoming LOE in Europe, partially offset by US growth.

Risks and Challenges:

• Generic erosion impacting legacy portfolio products, specifically Updevo, which declined 6% due to conversion to Cuvantic.
• Potential LOE for Eliquis in Europe expected to impact Q4 and result in a $1.5–$2 billion revenue step-down in 2027.
• ZolaCell program in autoimmune diseases currently paused pending review of a fatal sepsis pneumonia case (unrelated to previous pause, root cause identified as reagent activation change); program anticipated to restart soon.
• Mixed dose results for Admilpirant (120mg not statistically significant in IPF) require further analysis and future readouts in PPF.

Management Commentary and Tone:

• Tone is confident and forward-looking, emphasizing a "highly disciplined" approach to operations and a strong pipeline flow.
• Management expressed satisfaction with the acceleration of late-stage pipeline momentum, citing four positive Phase 3 readouts in the last two months.
• Chris Berner (CEO) highlighted the strategic flexibility gained from strong cash flows to invest in R&D, business development, and shareholder returns.
• Emphasis placed on "rewiring" operations to become faster and more efficient in R&D and manufacturing.

Analyst Questions and Answers:

• Admilpirant Dosing: Confirmed 60mg met endpoints; 120mg showed trend but not statistical significance; both doses being evaluated for the Phase 3 PPF study.
• Zembexis Launch: Early adoption positive driven by efficacy (MRD results) and simplicity; expected majority use in community settings (70–80%).
• Melvexian (SSP): Confidence remains high based on Phase 2 data and specific patient selection criteria; primary endpoint details expected in a press release with sufficient nuance.
• CoBentfi Growth: Inventory destocking in Q3 temporarily masked volume growth; focus on educating physicians on rapid titration to 125mg to manage GI side effects.
• AI & R&D: Progress on AI integration reported to reduce drug testing timelines by 20–30% and accelerate lead identification; partnerships with Anthropic and NVIDIA cited as active examples.
• Business Development: BD remains a top priority; company is financially disciplined and agnostic on deal size, focusing on strategic fit and value creation in core therapeutic areas.
• RAISE-101 Regulatory Path: Interim data supports regulatory engagement; team views RAISE Bio as a true IND engine for future oncology expansion.

Other Key Points:

• Manufacturing Investments: Two major US facilities announced: a $2.3B state-of-the-art campus in Houston (500 jobs) and a $170M radiopharmaceutical facility in Indiana (100 jobs by 2029).
• Pipeline Diversity: Company now has eight growth medicines annualizing over $1 billion, providing a broad base of growth drivers beyond the legacy portfolio.
• Safety Pause Resolution: ZolaCell pause resolved by adjusting reagent selection/activation; fatal event isolated (1 of 190 patients); program continues with rigorous oversight.
• Data Presentations: Significant data (Zembexis PFS, Admilpirant, CoBentfi ADEPT studies) scheduled for presentation at ASH (December) and CTAD (next month).